• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Is iguratimod effective in refractory axial spondyloarthritis?

作者信息

Luo Y, Zheng N, Wu R

机构信息

a Department of Rheumatology and Immunology , The First Affiliated Hospital of Nanchang University , Nanchang City , PR China.

出版信息

Scand J Rheumatol. 2018 Nov;47(6):518-520. doi: 10.1080/03009742.2017.1390150. Epub 2018 Feb 7.

DOI:10.1080/03009742.2017.1390150
PMID:29409372
Abstract
摘要

相似文献

1
Is iguratimod effective in refractory axial spondyloarthritis?艾拉莫德对难治性中轴型脊柱关节炎有效吗？
Scand J Rheumatol. 2018 Nov;47(6):518-520. doi: 10.1080/03009742.2017.1390150. Epub 2018 Feb 7.
2
Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study.艾拉莫德与安慰剂及柳氮磺胺吡啶治疗活动性类风湿关节炎的疗效和安全性比较：一项对照、多中心、双盲、平行组研究
Mod Rheumatol. 2007;17(1):1-9. doi: 10.1007/s10165-006-0542-y. Epub 2007 Feb 20.
3
Iguratimod ameliorates inflammatory responses by modulating the Th17/Treg paradigm in dextran sulphate sodium-induced murine colitis.艾拉莫德通过调节硫酸葡聚糖钠诱导的小鼠结肠炎中的Th17/Treg模式来改善炎症反应。
Mol Immunol. 2018 Jan;93:9-19. doi: 10.1016/j.molimm.2017.10.008. Epub 2017 Nov 6.
4
Lack of efficacy of tocilizumab in severe axial refractory spondyloarthritis: a report of 5 patients.托珠单抗治疗严重中轴型难治性脊柱关节炎无效：5例报告
Clin Exp Rheumatol. 2012 Sep-Oct;30(5):805. Epub 2012 Oct 17.
5
Iguratimod for the treatment of rheumatoid arthritis in Japan.艾拉莫德在日本用于治疗类风湿性关节炎。
Expert Rev Clin Immunol. 2015 May;11(5):565-73. doi: 10.1586/1744666X.2015.1027151. Epub 2015 Mar 22.
6
Long-term safety study of iguratimod in patients with rheumatoid arthritis.艾拉莫德治疗类风湿关节炎患者的长期安全性研究。
Mod Rheumatol. 2007;17(1):10-6. doi: 10.1007/s10165-006-0543-x. Epub 2007 Feb 20.
7
Abatacept in spondyloarthritis refractory to tumour necrosis factor alpha inhibition.阿巴西普用于对肿瘤坏死因子α抑制治疗无效的脊柱关节炎
Ann Rheum Dis. 2009 Jan;68(1):151-2. doi: 10.1136/ard.2008.097030.
8
Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod.在接受艾拉莫德治疗的类风湿关节炎患者中，治疗早期的疾病活动度作为未来低疾病活动度的预测指标。
Mod Rheumatol. 2016;26(2):169-74. doi: 10.3109/14397595.2015.1069475. Epub 2015 Aug 19.
9
Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.艾拉莫德与甲氨蝶呤联合治疗对甲氨蝶呤反应不足的活动性类风湿关节炎患者的安全性和有效性：一项随机、双盲、安慰剂对照试验的开放标签扩展研究
Mod Rheumatol. 2014 May;24(3):410-8. doi: 10.3109/14397595.2013.843756. Epub 2013 Nov 7.
10
Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid Arthritis.艾拉莫德对类风湿关节炎患者Th亚群平衡及炎性细胞因子的调控作用
Mediators Inflamm. 2015;2015:356040. doi: 10.1155/2015/356040. Epub 2015 Dec 2.

引用本文的文献

1
A systematic review and meta-analysis of the efficacy and safety of iguratimod in the treatment of inflammatory arthritis and degenerative arthritis.艾拉莫德治疗炎性关节炎和退行性关节炎的疗效与安全性的系统评价和荟萃分析。
Front Pharmacol. 2024 Oct 10;15:1440584. doi: 10.3389/fphar.2024.1440584. eCollection 2024.
2
Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases.依那西普治疗类风湿关节炎的临床疗效及安全性的Meta 分析
Front Immunol. 2023 Sep 21;14:1150661. doi: 10.3389/fimmu.2023.1150661. eCollection 2023.
3
Efficacy and safety of Iguratimod in the treatment of Ankylosing Spondylitis: A systematic review and meta-analysis of randomized controlled trials.
依那西普治疗强直性脊柱炎的疗效和安全性：系统评价和随机对照试验的荟萃分析。
Front Immunol. 2023 Mar 3;14:993860. doi: 10.3389/fimmu.2023.993860. eCollection 2023.
4
Randomised, Double-Blind, Placebo-Controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis.艾拉莫德治疗活动性脊柱关节炎的随机、双盲、安慰剂对照研究
Front Med (Lausanne). 2021 Jun 2;8:678864. doi: 10.3389/fmed.2021.678864. eCollection 2021.
5
Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis.支持 IL-17/IL-23 轴在中轴型脊柱关节炎中作用的临床试验。
Front Immunol. 2021 Jun 2;12:622770. doi: 10.3389/fimmu.2021.622770. eCollection 2021.
6
Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis.艾拉莫德治疗强直性脊柱炎的分子机制及临床研究
Clin Rheumatol. 2021 Jan;40(1):25-32. doi: 10.1007/s10067-020-05207-z. Epub 2020 Jun 6.
7
Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape.艾拉莫德作为类风湿关节炎的新药：现状
Front Pharmacol. 2020 Feb 26;11:73. doi: 10.3389/fphar.2020.00073. eCollection 2020.
8
Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology.艾拉莫德：一种来自亚太地区的用于改善自身免疫性疾病和保护骨骼生理功能的珍贵药物。
Bone Res. 2019 Sep 3;7:27. doi: 10.1038/s41413-019-0067-6. eCollection 2019.